Illinois is currently home to 2642 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Extended High-frequency Hearing and Speech Perception
NCT05435989
Recruiting
This study examines the effects of low-pass filtering speech on speech perception.
Gender:
ALL
Ages:
Between 19 years and 50 years
Trial Updated:
05/08/2023
Locations: University of Illinois Urbana-Champaign, Champaign, Illinois
Conditions: Low-pass Filtering Speech
Register for Updates
Anti-Inflammatory Milk Matrix
NCT04216004
Recruiting
Obesity is pro-inflammatory, impairs metabolism, and physically limiting. Specifically, muscle in obese persons does not synthesize proteins normally. This further increases metabolic and physical dysfunction. As such, obesity programs should not only focus on weight loss, but muscle metabolic health. Dairy nutrients have anti-inflammatory and anabolic properties, but mostly evaluated in isolation and/or pre-clinical designs. Also, it is unknown if the circulating benefits extend to the muscle.... Read More
Gender:
ALL
Ages:
Between 40 years and 59 years
Trial Updated:
05/08/2023
Locations: Freer Hall, Urbana, Illinois
Conditions: Obesity, Skeletal Muscle, Inflammation
Register for Updates
Comprehensive Care Community and Culture Study
NCT04489693
Recruiting
This randomized trial is evaluating whether socioeconomically disadvantaged Medicare patients at increased risk of hospitalization experience fewer hospitalization if those patients are offered care in: 1) ACCT, where patients receive care from different physicians in the hospital and the clinic settings and have access to nurse and social worker care coordination services, 2) CCP where patients receive care from one physician in the inpatient and outpatient settings or 3) C4P which adds screeni... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2023
Locations: David Meltzer, Chicago, Illinois
Conditions: Comprehensive Care, Quality of Care, Medicare, Cost of Care
Register for Updates
Mesh-Reduced Sling For Treating Stress Urinary Incontinence, Efficacy and Durability Trial
NCT05842005
Recruiting
The goal of this pilot study is to report the safety and efficacy of a suture-suspended mesh-reduced sling for treating stress urinary incontinence (SUI) in women. The main question\[s\] it aims to answer are: * investigate the efficacy of this mesh-reduced suture-based surgical technique for improving SUI symptoms * investigate the efficacy of this mesh-reduced suture-based surgical technique on key urethral support defects observed with 3D ultrasound Participants will consent to participate... Read More
Gender:
FEMALE
Ages:
Between 45 years and 100 years
Trial Updated:
05/02/2023
Locations: NorthShore University Health System, Skokie, Illinois
Conditions: Stress Urinary Incontinence
Register for Updates
Keeping it LITE: Exploring HIV Risk in Vulnerable Youth With Limited Interaction and Digital Health Intervention
NCT05848570
Recruiting
Despite advances in HIV diagnostics, care and prevention strategies, infection rates among adolescent and young adult sexual and gender minorities (SGM) continue to rise in the United States (US). There is an urgent need to describe the epidemiology and trajectories of HIV acquisition in this population and to offer age and culturally appropriate scalable prevention interventions to those at highest risk of infection in the US. This project will engage and retain young SGM in an innovative longi... Read More
Gender:
ALL
Ages:
Between 13 years and 34 years
Trial Updated:
04/27/2023
Locations: John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois
Conditions: HIV Infections, Sexual Behavior
Register for Updates
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
NCT03945162
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-012 - University of Chicago, Chicago, Illinois
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Register for Updates
Enhancing Children's Cognitive Function and Achievement Through Carotenoid Consumption
NCT05177679
Recruiting
The aim of this study is to test the casual relationship between carotenoid supplementation, cognitive function, and achievement over a school-year. The central hypothesis is that, relative to the waitlist placebo group, children receiving the carotenoid supplement will exhibit greater gains in cognitive function and achievement.
Gender:
ALL
Ages:
Between 8 years and 10 years
Trial Updated:
04/26/2023
Locations: University of Illinois Urbana-Champaign, Urbana, Illinois
Conditions: Cognitive Change, Achievement, Macular Pigmentation
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
NCT05503355
Recruiting
An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will define the maximal tolerate dose of the combination treatment, while part 2 will expend the chosen dose, to assesses efficacy and safety of this combination. All patients will receive 2 induction courses with both BST-236 and venetoclax, responding patients will then be... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2023
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: AML, Adult
Register for Updates
Physica System Total Knee Replacement Registry Study
NCT03048201
Recruiting
The primary objective of this study is to obtain long-term implant survivorship (out to 10 years) and to assess clinical, patient-reported outcome measures, and radiographic data for the commercially available Physica system. For ancillary arm, from baseline to 5-year follow-up.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/17/2023
Locations: Rush Castle Orthopaedics, Aurora, Illinois
Conditions: Osteoarthritis, Knee, Traumatic Arthritis, Avascular Necrosis, Degenerative Joint Disease of Knee, Rheumatoid Arthritis, Deformity of Knee
Register for Updates
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT05733000
Recruiting
This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that have not responded to chemotherapy medications (chemorefractory). Metabolism is how the cells in the body use molecules (carbohydrates, fats, and proteins) from food to get the energy they nee... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2023
Locations: Northwestern University, Chicago, Illinois
Conditions: Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Urothelial Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Urothelial Carcinoma, Refractory Biliary Tract Carcinoma, Refractory Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Urothelial Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Register for Updates
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
NCT05554068
Recruiting
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
Gender:
ALL
Ages:
All
Trial Updated:
03/07/2023
Locations: Loyola University Medical Center, Maywood, Illinois
Conditions: Shingles
Register for Updates